Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Change of initial oral antidiabetic therapy in type 2 diabetic patients.

Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R.

Pharm World Sci. 2009 Dec;31(6):622-6. doi: 10.1007/s11096-009-9321-0. Epub 2009 Aug 20.

PMID:
19690978
2.

Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.

Levin PA, Wei W, Zhou S, Xie L, Baser O.

J Manag Care Spec Pharm. 2014 May;20(5):501-12.

4.

Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.

Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:8-15. doi: 10.1111/j.1463-1326.2008.00881.x.

PMID:
18435669
5.

Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.

Rascati K, Richards K, Lopez D, Cheng LI, Wilson J.

Diabetes Obes Metab. 2013 Oct;15(10):901-5. doi: 10.1111/dom.12103. Epub 2013 Apr 18.

PMID:
23531154
6.

Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study.

Penning-van Beest FJ, Wolffenbuttel BH, Herings RM.

Clin Drug Investig. 2008;28(8):487-93.

PMID:
18598094
7.

Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.

Inagaki N, Watada H, Murai M, Kagimura T, Gong Y, Patel S, Woerle HJ.

Diabetes Obes Metab. 2013 Sep;15(9):833-43. doi: 10.1111/dom.12110. Epub 2013 May 3.

PMID:
23565760
8.

Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.

Rajpathak SN, Rajgopalan S, Engel SS.

J Diabetes Complications. 2014 Nov-Dec;28(6):831-5. doi: 10.1016/j.jdiacomp.2014.06.004. Epub 2014 Jun 19.

PMID:
25104238
9.

Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.

Saab C, Al-Saber FA, Haddad J, Jallo MK, Steitieh H, Bader G, Ibrahim M.

Vasc Health Risk Manag. 2015 Feb 24;11:149-55. doi: 10.2147/VHRM.S73703. eCollection 2015.

10.

Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.

Musholt PB, Schöndorf T, Pfützner A, Hohberg C, Kleine I, Fuchs W, Hehenwarter S, Dikta G, Kerschgens B, Forst T.

J Diabetes Sci Technol. 2009 Nov 1;3(6):1442-50.

11.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
12.

Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study.

Yu S, Schwab P, Bian B, Radican L, Tunceli K.

J Manag Care Spec Pharm. 2016 Mar;22(3):272-80. doi: 10.18553/jmcp.2016.22.3.272.

13.

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.

Fonseca V, Gill J, Zhou R, Leahy J.

Diabetes Obes Metab. 2011 Sep;13(9):814-22. doi: 10.1111/j.1463-1326.2011.01412.x.

14.

Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes.

Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA.

Diabetes Obes Metab. 2008 Aug;10(8):638-45. Epub 2007 Jul 21.

PMID:
17645555
15.

Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes.

Lin SD, Tsai ST, Tu ST, Su CC, Chen JF, Lu CH, Wang CH, Yu NC, Hsu SR, Hsieh MC.

Prim Care Diabetes. 2015 Apr;9(2):135-41. doi: 10.1016/j.pcd.2014.05.005. Epub 2014 Sep 27.

PMID:
25266893
16.

Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.

Vichayanrat A, Matawaran BJ, Wibudi A, Ferdous HS, Aamir AH, Aggarwal SK, Bajpai S.

J Diabetes. 2013 Sep;5(3):309-18. doi: 10.1111/1753-0407.12038. Epub 2013 May 28.

PMID:
23462227
17.

Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China.

Zhang L, Ji L, Guo L, Lu J, Tian H, Zhu D, Xing X, Weng JP, Jia W.

Diabetes Technol Ther. 2015 Nov;17(11):816-24. doi: 10.1089/dia.2015.0094. Epub 2015 Oct 8.

PMID:
26448574
18.

Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany.

Kostev K, Dippel FW.

Prim Care Diabetes. 2012 Dec;6(4):329-35. doi: 10.1016/j.pcd.2012.06.001. Epub 2012 Jun 30.

PMID:
22749713
19.

Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study.

Gómez-Peralta F, Carramiñana-Barrera F, Félix-Redondo FJ, Fraile-Gómez J; Extreme Rescue Study Group.

Int J Clin Pract. 2012 Oct;66(10):959-68. doi: 10.1111/j.1742-1241.2012.03000.x.

PMID:
22994330
20.

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

Nauck M, Marre M.

Postgrad Med. 2009 May;121(3):5-15. doi: 10.3810/pgm.2009.05.1997.

PMID:
19491535

Supplemental Content

Support Center